Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Obstetrix DHA is a multivitamin and multi-mineral dietary supplement combined with omega-3 fatty acids, specifically docosahexaenoic acid (DHA). Developed and marketed by Seyer Pharmatec, it is designed to improve the nutritional status of women during pregnancy and the postnatal period, including both lactating and non-lactating mothers. The DHA component, derived from purified fish oil, is intended to support fetal brain and eye development. The product typically consists of a combination pack containing DHA softgels and prenatal vitamin tablets. As a dietary supplement, it provides essential nutrients such as folate (as l-5-methyltetrahydrofolate calcium), iron (as carbonyl iron), and various vitamins to support maternal health and fetal growth rather than targeting a specific pharmacological pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Obstetrix DHA.